leisure time -WSS

leisure time

author：leisure time 2025-08-10 11:42:44 - browse：443

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Readout Newsletter: The latest on Moderna, Apellis, and Merck

WSS

David Ricks of Eli Lilly: best biopharma CEO of 2023

Researchers tackle phage therapy hurdles for wider adoption

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Measles policy set amid Florida outbreak alarms vaccine proponents

Measles policy set amid Florida outbreak alarms vaccine proponents

Christmas in the PICU brings some surprising joy

knowledge

leisure time

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Reporting on presidential health from Reagan to Trump and Biden

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CRISPR gene editing developments we’re watching in 2024

Apple is now the first public company to be valued at $3 trillion

Carvykti CAR

DIEP, the 'gold standard' of breast reconstruction, is under threat

MD Anderson's Padmanee Sharma responds to research credit suit

Heart attack and stroke risk calculators need revising

New study raises questions about niacin and heart health

Wikipedia

Researchers tackle phage therapy hurdles for wider adoption

SNAP should offer more nutrition education

Ukraine seeks to reclaim its role as a hub for clinical trials

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Measles policy set amid Florida outbreak alarms vaccine proponents

Secretariat’s lessons for human medicine

entertainment

leisure time

focus

focus